Supriya Lifescience Balance Sheet Health
Financial Health criteria checks 6/6
Supriya Lifescience has a total shareholder equity of ₹9.1B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹10.1B and ₹1.1B respectively. Supriya Lifescience's EBIT is ₹5.1B making its interest coverage ratio 1.7. It has cash and short-term investments of ₹843.1M.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | 1.7x |
| Cash | ₹843.14m |
| Equity | ₹9.06b |
| Total liabilities | ₹1.07b |
| Total assets | ₹10.12b |
Recent financial health updates
No updates
Recent updates
Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 07
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
Sep 08We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Jun 05Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Financial Position Analysis
Short Term Liabilities: SUPRIYA's short term assets (₹4.1B) exceed its short term liabilities (₹754.4M).
Long Term Liabilities: SUPRIYA's short term assets (₹4.1B) exceed its long term liabilities (₹310.6M).
Debt to Equity History and Analysis
Debt Level: SUPRIYA is debt free.
Reducing Debt: SUPRIYA has no debt compared to 5 years ago when its debt to equity ratio was 70.8%.
Debt Coverage: SUPRIYA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SUPRIYA has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:35 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Supriya Lifescience Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | K.R. Choksey Shares & Securities Private Ltd. |